Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials

JACC: Cardiovascular Interventions

Volumn 9, Issue 16, 2016, Pages 1731-1742

  Giacoppo, Daniele ^a   Cassese, Salvatore ^a   Harada, Yukinori ^a   Colleran, Roisin ^a   Michel, Jonathan ^a   Fusaro, Massimiliano ^a   Kastrati, Adnan ^a,b   Byrne, Robert A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

balloon angioplasty; drug coated balloon; meta analysis; peripheral arterial disease

Indexed keywords

PACLITAXEL; BIOCOMPATIBLE COATED MATERIAL; CARDIOVASCULAR AGENT;

ARTICLE; DRUG COATED BALLOON; ECHOGRAPHY; FEMORAL ARTERY; FOLLOW UP; HUMAN; LEG REVASCULARIZATION; META ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; ADVERSE EFFECTS; DEVICES; DIAGNOSTIC IMAGING; EQUIPMENT DESIGN; MORTALITY; ODDS RATIO; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; RISK FACTOR; STENOSIS, OCCLUSION AND OBSTRUCTION; TIME FACTOR; TREATMENT OUTCOME; VASCULAR ACCESS DEVICE; VASCULAR PATENCY;

ANGIOPLASTY, BALLOON; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; EQUIPMENT DESIGN; FEMORAL ARTERY; HUMANS; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES; VASCULAR PATENCY;

EID: 84990973720     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.06.008     Document Type: Article

References (39)

1. 1 Tendera, M., Aboyans, V., Bartekink, M.L., et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J 32 (2011), 2851–2906.
2. 2 Norgren, L., Hiatt, W.R., Dormandy, J.A., et al. Inter–Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surgery 33:Suppl 1 (2007), S1–S75.
3. 3 Schillinger, M., Sabeti, S., Loewe, C., et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 354 (2006), 1879–1888.
4. 4 Krankenberg, H., Schluter, M., Steinkamp, H.J., et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation 116 (2007), 285–292.
5. 5 Dake, M.D., Ansel, G.M., Jaff, M.R., et al. Sustained safety and effectiveness of paclitaxel–eluting stents for femoropopliteal lesions: 2–year follow–up from the Zilver PTX randomized and single–arm clinical studies. J Am Coll Cardiol 61 (2013), 2417–2427.
6. 6 Rosenfield, K., Jaff, M.R., White, C.J., et al. Trial of a paclitaxel–coated balloon for femoropopliteal artery disease. N Engl J Med 373 (2015), 145–153.
7. 7 Tepe, G., Zeller, T., Albrecht, T., et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 358 (2008), 689–699.
8. 8 Krankenberg, H., Tubler, T., Ingwersen, M., et al. Drug–coated balloon versus standard balloon for superficial femoral artery in–stent restenosis: the Randomized Femoral Artery In–Stent Restenosis (FAIR) Trial. Circulation 132 (2015), 2230–2236.
9. 9 Byrne, R.A., Joner, M., Alfonso, F., et al. Drug–coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol 11 (2014), 13–23.
10. 10 Cassese, S., Byrne, R.A., Ott, I., et al. Paclitaxel–coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta–analysis of randomized trials. Circ Cardiovasc Interv 5 (2012), 582–589.
11. 11 Fusaro, M., Cassese, S., Ndrepepa, G., et al. Paclitaxel–coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta–analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. Int J Cardiol 168 (2013), 4002–4009.
12. 12 Katsanos, K., Spiliopoulos, S., Karunanithy, N., Krokidis, M., Sabharwal, T., Taylor, P., Bayesian network meta–analysis of nitinol stents, covered stents, drug–eluting stents, and drug–coated balloons in the femoropopliteal artery. J Vasc Surg 59 (2014), 1123–1133.e8.
13. 13 Cortese, B., Granada, J.F., Scheller, B., et al. Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. Eur Heart J 37 (2016), 1096–1103.
14. 14 Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta–analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, 2009, b2700.
15. 15 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 5.1.0 [Updated March 2011]. Available at: www.cochrane–handbook.org. 2011. Accessed December 10, 2015.
16. 16 DerSimonian, R., Laird, N., Meta–analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
17. 17 Borenstein, M., Hedges, L.V., Higgins, J.P.T., Rothstein, H.R., Introduction to meta–analysis. 2009, John Wiley & Sons, West Sussex (UK).
18. 18 Bagos, P.G., Nikopoulos, G.K., Mixed–effects Poisson regression models for meta–analysis of follow–up studies with constant or varying durations. Int J Biostat 5 (2009), 1–33.
19. 19 Spiegelhalter, D., Abrams, K., Myles, J., Bayesian approaches to clinical trials and health–care evaluation. Statistics in practice. 2004, John Wiley and Sons, New York.
20. 20 Dias, S., Sutton, A.J., Welton, N.J., et al. Evidence synthesis for decision making 6: embedding evidence synthesis in probabilistic cost–effectiveness analysis. Med Decis Making 33 (2013), 671–678.
21. 21 Lambert, P.C., Sutton, A.J., Burton, P.R., et al. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 24 (2005), 2401–2428.
22. 22 Brooks, S.P., Gelman, A., General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7 (1998), 434–455.
23. 23 Wetterslev, J., Thorlund, K., Brok, J., Gluud, C., Trial sequential analysis may establish when firm evidence is reached in cumulative meta–analysis. J Clin Epidemiol 61 (2008), 64–75.
24. 24 Wetterslev, J., Thorlund, K., Brok, J., et al. Estimating required information size by quantifying diversity in random–effects model meta–analyses. BMC Med Res Methodol, 9, 2009, 86.
25. 25 Scheinert, D., Schulte, K.L., Zeller, T., et al. Paclitaxel–releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve–month results from the BIOLUX P–I randomized trial. J Endovasc Ther 22 (2015), 14–21.
26. 26 Werk, M., Langner, S., Reinkensmeier, B., et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel–coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 118 (2008), 1358–1365.
27. 27 Tepe, G., Laird, J., Schneider, P., et al. Drug–coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12–month results from the IN.PACT SFA randomized trial. Circulation 131 (2015), 495–502.
28. 28 Scheinert, D., Duda, S., Zeller, T., et al. The LEVANT I (Lutonix paclitaxel–coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first–in–human randomized trial of low–dose drug–coated balloon versus uncoated balloon angioplasty. J Am Coll Cardiol Intv 7 (2014), 10–19.
29. 29 Werk, M., Albrecht, T., Meyer, D.R., et al. Paclitaxel–coated balloons reduce restenosis after femoro–popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv 5 (2012), 831–840.
30. 30 Laird, J.R., Schneider, P.A., Tepe, G., et al. Durability of treatment effect using a drug–coated balloon for femoropopliteal lesions: 24–month results of IN.PACT SFA. J Am Coll Cardiol 66 (2015), 2329–2338.
31. 31 Tepe, G., Schnorr, B., Albrecht, T., et al. Angioplasty of femoral–popliteal arteries with drug–coated balloons: 5–year follow–up of the THUNDER trial. J Am Coll Cardiol Intv 8 (2015), 102–108.
32. 32 Xu, B., Qian, J., Ge, J., et al. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: a prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis. Catheter Cardiovasc Interv 87 (2016), 624–629.
33. 33 Kufner, S., Cassese, S., Valeskini, M., et al. Long–Term efficacy and safety of paclitaxel–eluting balloon for the treatment of drug–eluting stent restenosis: 3–year results of a randomized controlled trial. J Am Coll Cardiol Intv 8 (2015), 877–884.
34. 34 Dake, M.D., Ansel, G.M., Jaff, M.R., et al. Paclitaxel–eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve–month Zilver PTX randomized study results. Circ Cardiovasc Interv 4 (2011), 495–504.
35. 35 Sterne, J.A., Sutton, A.J., Ioannidis, J.P., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta–analyses of randomised controlled trials. BMJ, 343, 2011, d4002.
36. 36 Kelsch, B., Scheller, B., Biedermann, M., et al. Dose response to Paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Invest Radiol 46 (2011), 255–263.
37. 37 Radke, P.W., Joner, M., Joost, A., et al. Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. EuroIntervention 7 (2011), 730–737.
38. 38 Yazdani, S.K., Pacheco, E., Nakano, M., et al. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv 83 (2014), 132–140.
39. 39 Thompson, S.G., Higgins, J.P., How should meta–regression analyses be undertaken and interpreted?. Stat Med 21 (2002), 1559–1573.